DDIT3 and diffuse large B-cell lymphoma: The inclusion of Rituximab in the treatment composed of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) greatly improved the chemotherapy response and survival of the DLBCL patients.